期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Computational Assessment and Pharmacological Property Breakdown of Eight Patented and Candidate Drugs against Four Intended Targets in Alzheimer’s Disease
1
作者 Bishajit Sarkar Syed Sajidul Islam +4 位作者 Md. Asad Ullah Sohana Hossain Md. Nazmul Islam Prottoy Yusha Araf Masuma Afrin Taniya 《Advances in Bioscience and Biotechnology》 2019年第11期405-430,共26页
Alzheimer’s Disease (AD) is the most prevalent age-related dementia. AD can be caused by abnormal processing of amyloid precursor protein (APP) or by oxidative stress or may be due to the actions of kinases or the de... Alzheimer’s Disease (AD) is the most prevalent age-related dementia. AD can be caused by abnormal processing of amyloid precursor protein (APP) or by oxidative stress or may be due to the actions of kinases or the degeneration and loss of functions of neurons in the brain. Although various treatments have already gained success in the in vitro studies, however, till now not a single satisfactory drug has been proven that can cure this disease permanently till now. In this study, the best possible drug has been determined from a group of drug molecules using methods of molecular docking. Molecular docking is a computational approach which helps to determine the best molecule from a group of molecules which may bind with the highest affinity with the intended target by mimicking the original biological environment in a computer. The tested drug molecules in this experiment are the disease modifying agents, capable of inhibiting a particular protein involving in the AD pathway. Eight drug molecules (ligands)-memantine (-4.075 Kcal/mol), hymenialdisine (-8.079 Kcal/mol), tideglusib (-6.445 Kcal/mol), kenpaullone (-7.545 Kcal/mol), dihydrospiro[dibenzo[a,d][7]annulene-5,4’-imidazol] (-4.742 Kcal/mol), harmine (-7.57 Kcal/mol), harmol (-6.583 Kcal/mol) and 1-Methyl-4-Phenylpyridinium (-5.214 Kcal/mol), have been docked successfully against four targets (proteins)-N-Methyl-D-Aspartate Receptor (NMDAR), glycogen synthase kinase-3β (GSK-3β), beta-secretase (β-secretase) and dual specificity tyrosine (Y)-phosphorylation-regulated kinase 1A (DYR-K1A) in this experiment which are intended targets in current AD treatment approaches. Investigation of docking results, druglikeness properties and ADME/T testing results suggest that the best findings of this experiment are memantine, hymenialdisine, dihydrospiro[dibenzo[a,d][7]annulene-5,4’-imi- dazol] and harmol, that could be the best possible drugs for the treatment of AD. 展开更多
关键词 Alzheimer’s Disease harmol Β-SECRETASE DOCKING Tau Protein Β-AMYLOID
下载PDF
Streptomyces griseus ATCC 13273对去氢骆驼蓬碱的转化研究 被引量:1
2
作者 李琳 向文 +1 位作者 余伯阳 刘吉华 《药物生物技术》 CAS CSCD 2012年第4期299-303,共5页
利用微生物转化的方法,选取灰色链霉菌(Streptomyces griseus ATCC 13273)为转化菌株,对去氢骆驼蓬碱的转化进行研究。该菌株可以将去氢骆驼蓬碱转化为两种转化产物(记为H1和H2),通过MS、1H-NMR和13C-NMR分析,转化产物分别鉴定为哈尔酚... 利用微生物转化的方法,选取灰色链霉菌(Streptomyces griseus ATCC 13273)为转化菌株,对去氢骆驼蓬碱的转化进行研究。该菌株可以将去氢骆驼蓬碱转化为两种转化产物(记为H1和H2),通过MS、1H-NMR和13C-NMR分析,转化产物分别鉴定为哈尔酚和N-羟基去氢骆驼蓬碱。并对转化条件进行初步优化,优化后的转化条件为:初始pH 8.0,两步活化法以4%的接种量转接,48 h后加入底物(以N,N-二甲基甲酰胺溶解),发酵液中去氢骆驼蓬碱终浓度为0.25 mmoL/L,发酵时间为5 d。转化条件优化后H1和H2的产率分别达到8.70%和12.76%;该研究丰富了S.griseus ATCC 13273的作用底物范围,为哈尔酚和N-羟基去氢骆驼蓬碱的合成提供了一条新途径。 展开更多
关键词 灰色链霉菌 去氢骆驼蓬碱 哈尔酚 N-羟基去氢骆驼蓬碱 微生物转化 产率
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部